Introduction
Expression of the c-myc proto-oncogene is closely linked to cellular proliferation and to the capacity for differentiation in many cell types. Overexpression of c-myc promotes cell cycle progression, but usually results in apoptosis in cells deprived of survival signals (reviewed in Refs 1, 2). c-myc in co-operation with other oncogenes induces malignant transformation of primary cells in culture and in transgenic mice. The observation of chromosomal aberrations involving members of the proto-oncogene myc family (c-myc, N-myc and L-myc) in several types of human cancer is also consistent with an important role in tumorigenesis. Examples of such aberrations are the L-, N-and c-myc amplifications in small cell lung carcinoma (SCLC), c-myc amplification in breast carcinoma, Nmyc amplification in neuroblastoma, and c-myc translocations in Burkitt's lymphoma (reviewed in Refs 1, [3] [4] [5] . Experimental evidence that deregulated expression of c-myc inhibits induced differentiation in hematopoietic and other cell types, that would normally downregulate myc expression upon differentiation, lends further support to this notion. Initially, erythroid differentiation was shown to be blocked by constitutive expression of c-myc in murine erythroleukemia (MEL) cells, [6] [7] [8] followed by observations demonstrating inhibition of differentiation by myc oncogenes in several hemato- poietic and other cell lines. [9] [10] [11] [12] [13] [14] [15] [16] Conversely, c-myc anti-sense oligonucleotides have been shown to induce differentiation of HL-60 and F9 cells. 17, 11 c-Myc belongs to the basic/helix-loop-helix/leucine zipper (bHLHZip) family of transcription factors and requires heterodimerization with a partner, the bHLHZip protein Max, to exert its function. 18, 19 c-Myc:Max heterodimers have been suggested to activate transcription of a number of genes involved in cell growth and cell cycle control by binding to so-called E-box regulatory elements in these genes (reviewed in Refs 2, 20, 21) . In addition, Max heterodimerizes with the Mad/Mnt-family of proteins which act as transcriptional repressors, and may compete with Myc for binding to Max and/or for binding to Myc-regulated E-box elements, thereby turning off transcription of target genes for c-Myc:Max (for review see Refs 1, 22, 23) . In contrast to c-Myc most of the Mad family genes are expressed in quiescent, differentiated cells. It has therefore been suggested that c-Myc, Max, and the Mad family proteins form a network of transcriptional activators and repressors that influence cell fate decisions during cell growth and differentiation.
Induced terminal differentiation of the human monoblastic cell line U-937 is associated with the acquisition of a monocyte-macrophage morphology, upregulation of differentiation-related antigens, irreversible growth arrest in the G 1 /G 0 phase of the cell cycle and downregulation of c-Myc expression. 12, 24 We have shown previously that constitutive expression of a v-myc gene inhibits phorbol ester (TPA)-, vitamin D 3 -and retinoic acid-induced terminal differentiation of U-937 cells. 12 However, costimulation by IFN-␥ can permanently restore terminal differentiation in these cells despite continuous expression of the v-Myc protein. 24 A potential mechanism underlying this effect was suggested by our recent demonstration that IFN-␥ induces the destabilization of Myc:Max heterodimers and inhibition of Myc-dependent transcriptional activity, thus indicating that external signals can affect Myc function post-translationally. 25 This raises the question whether cytokines other than IFN-␥ could be used to restore differentiation and growth arrest in tumor cells transformed by Myc. In this study, we utilized the v-Myc expressing U-937 cell lines to investigate the differentiation-inducing capacity of 16 cytokines that, to various extents, are known to affect monocytic growth and differentiation. The cytokines chosen were interleukin 1 (IL-1), IL-3, IL-4, IL-6, IL-7, IL-10, IL-11, leukemia inhibitory factor (LIF), oncostatin M (OSM), the colony-stimulating factors M-CSF, G-CSF and GM-CSF, and transforming growth factor ␤ (TGF␤1), tumor necrosis factor ␣ (TNF-␣), interferon (IFN) ␣ and IFN-␥. Specifically, we sought to answer the following questions: (1) can cytokines be used to induce differentiation of a cell line transformed by v-Myc, either as single agents or in combination with TPA; (2) will the differentiation be associated with suppression of proliferation and/or G 1 /G 0 arrest in the cell cycle; and (3) does cytokine-induced differentiation result in changes in the expression and/or activity of the v-Myc protein?
Materials and methods

Cell culture and reagents
U-937 is a human monoblastic cell line established from a patient with histiocytic lymphoma. 26 The G-418-resistant U-937 clones, containing the OK10 v-myc oncogene as part of the retroviral construct MMCV-neo (U-937-MMCV-2 and U-937-MMCV-6), and a control clone containing a similar retroviral construct MV-4-neo (U-937-MV-4-6) lacking the v-myc gene, were derived from the U-937-GTB subline. 12 In this paper, the U-937-MMCV-2, U-937-MMCV-6 and U-937-MV-4-6 clones are, for simplicity, referred to as the U-937-myc-2 and myc-6 and the neo-6 clone, respectively. All cells were cultured in RPMI 1640 medium supplemented with glutamine, antibiotics and 7.5% fetal calf serum (FCS; Gibco, Uxbridge, UK).
Induction of differentiation
U-937 cells, at a concentration of 2 × 10 5 /ml, were stimulated in medium containing 1.6 × 10 −7 M TPA (Sigma, St Louis, MO, USA), or cytokines as single agents, or a combination of TPA and cytokine (costimulation). Unless otherwise indicated the cytokines and concentrations used were: rIFN-␥ (50 U/ml) and rTNF-␣ (0.2 ng/ml) (generously provided by Dr GR Adolf, Ernst-Boehringer Inst. Vienna, Austria), rIFN␣2b (1000 U/ml), rIL-4 (25 ng/ml) and G-CSF (100 U/ml) (kind gifts from Schering Corporation, Stockholm, Sweden), rIL-1␤ (100 U/ml) and rIL-7 (200 U/ml) (kind gifts from Dr S Gillis, Immunex Corporation, Seattle, WA, USA), IL-3 (200 U/ml), IL-11 (100 U/ml), M-CSF (1000 U/ml) and GM-CSF (100 ng/ml) (generously provided by Dr S Clark, Genetics Institute, Cambridge, MA, USA) rIL-6 (100 U/ml) (kindly provided by Dr T Kishimoto, Osaka, Japan or purchased from R&D Systems, Abingdon, UK), TGF␤1 (1 ng/ml) (generously provided by Dr M Sporn, NIH, Bethesda, MD, USA), Oncostatin-M (100 U/ml) and Leukemia Inhibitory Factor (0.5 ng/ml) (purchased from R&D Systems). Induction of differentiation was performed in tissue culture flasks coated with a thin layer of Agarose M (Pharmacia, Uppsala, Sweden) to prevent adhesion of the cells. Morphological differentiation was assessed by light microscopical examination of May-Grü newald-Giemsa stained cells, spun on to glass slides using a cytocentrifuge.
Immunofluorescence
The expression of CD11c (␣X-integrin subunit of the adhesion molecule p150.95) and CD11b (␣M-integrin of the CR3/Mac1 complex) was measured by immunofluorescence using flow cytometry (FACScan; Becton Dickinson, Mountain View, CA, USA). Briefly, the cells were washed twice with PBS, incubated with the primary ␣-CD11c antibody (LeuM5; Becton Dickinson) on ice for 30 min, washed twice, incubated on ice for 30 min with fluoroscein-isothiocyanate (FITC)-labeled goat-anti-mouse F(abЈ) 2 fragments (Janssen, Beerse, Belgium) and, finally washed twice with PBS + 0.5% FCS. CD11b was detected by a PE-conjugated antibody (Dako, Glostrup, Denmark). As controls for unspecific binding isotype-matched control antibodies were used.
Proliferation and cell cycle analysis
Cell numbers were measured from triplicate cultures using a Coulter Z1 cell counter (Luton, UK). DNA synthesis was determined by labeling cells for 1 h with 0.1 Ci 3 H-thymidine, followed by harvesting using a Titertek cell harvester (Skatron, Lier, Norway), whereafter the 3 H-TdR incorporation was measured using a 1214 Rackbeta Liquid Scintillation Counter (LKB/Wallac, Turku, Finland). For analysis of cell cycle phase distribution, cells were washed once in cold PBS, fixed in ice-cold 70% EtOH, centrifuged and resuspended at 5 × 10 6 cells/ml, thereafter treated with RNase A (Sigma; 0.08 mg/ml) for 20 min at RT, and finally stained by propidium iodide (PI; Sigma, 10 g/ml in PBS). The stained cells were subsequently analyzed using a FACScan (Becton Dickinson).
Analysis of apoptosis
To measure apoptosis, PE-conjugated Annexin V was used in combination with the vital dye/7-amino-actinomycin (7-AAD) (Pharmingen, San Diego, CA, USA) according to the manufacturer's recommendations. Briefly, the cells were washed twice in PBS, and Annexin V-PE binding was performed in a binding buffer (10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ) for 15 min at room temperature. The stained cells were analyzed using flow cytometry (FACScan; Becton Dickinson).
Northern blot analysis
Total cellular RNA was isolated by the LiCl/Urea method. 27 Ten g of total RNA per well were fractionated in an agarose gel containing 1% formaldehyde, and subsequently transferred on to a nitrocellulose filter (Hybond-C extra; Amersham, Buckingham, UK). 32 P-labeled probes were prepared (Megaprime DNA labeling systems; Amersham) using an EcoRI-HindIII fragment of a histone H4 cDNA clone 28 and a HindIII-XbaI fragment of a GAPDH cDNA clone. 29 Hybridization was performed at 42°C in a solution containing 50% formamide, 1 × Denhardt's solution, 2 × SSC (0.3 M sodium chloride and 30 mM sodium citrate), 5 mM NaPO 4 , 0.1% sodium dodecyl sulphate, and 200 g/ml of salmon sperm DNA. The filter was finally washed in 15 mM NaCl/15 mM sodium citrate/0.1% sodium dodecyl sulphate at 53°C for 3 × 30 min before autoradiography.
Immunoprecipitation and Western blot analysis
Immunoprecipitation was performed as described. 30 Briefly, 5 × 10 6 cells were washed in PBS and lysed under low stringency conditions in Tris lysis buffer (0.1 M Tris pH 8.0, 0.15 M NaCl, 5 mM EDTA, 1% NP-40, 1 mM phenylmethylsulphonyl fluoride (PMSF), 0.5% aprotinin, 0.5 g/ml pepstatin, 0.5 mM benzamidine, 2.5 g/ml leupeptin, 1 mM DTT) and immunoprecipitated with specific antibodies. Aliquots of lysates with equal amounts of protein were used for each sample. The immunoprecipitates were washed three times in Tris lysis buffer and the proteins were separated on 10-15% SDS-PAGE gels. The immunoblot and immunostaining procedures were Reduced Myc activity during cytokine-induced differentiation and growth arrest F Ö berg et al 219 performed as described previously. 30 The blots were developed by enhanced chemiluminescence (Amersham) using horseradish peroxidase (HRP)-conjugated anti-rabbit Ig (Amersham) for rabbit antisera or streptavidin-conjugated HRP (Amersham) for biotinylated antibodies.
For immunoprecipitation and Western blot analysis of Myc proteins, IG-13 rabbit pan-Myc antiserum 25 and biotinylated C-33 monoclonal pan-Myc antibodies (Santa Cruz Biotechnology (SCB) Santa Cruz, CA, USA) were used, respectively. Biotinylation was carried out as described. 25 For both immunoprecipitation and Western blot analysis of Max, C-17 rabbit Max antiserum (SCB) was used.
Transfections and assays for reporter activity
Electroporation and luciferase assays were performed as described. 25 Briefly, 2 × 10 7 cells were electroporated with 20 g of DNA in RPMI-1640 medium at 960 F, 300 V in a Biorad gene pulser (Hercules, CA, USA). After transfection, the cells from separate transfections were pooled and divided into aliquots, which were then treated with the inducers for 18 h. Cell extracts were prepared as described. 25 Luciferase and ␤-gal assays were performed by the Luciferase Reporter Assay System (Promega, Madison, WI, USA) and the ␤-Galactosidase Detection Kit (Clontech, Palo Alto, CA, USA), respectively, using a Lumat LB 9501/16 Berthold luminometer (Bad Wildbad, Germany). m4mintk-Luc, which contains a tetramer of an oligonucleotide containing the Myc:Max DNA binding site CACGTG in front of a minimal tk promoter (−32/+51) driving a luciferase reporter gene, was used for measurement of E-box-dependent transcription. 25 CMV-LacZ, which contains the ␤-gal gene driven by a CMV promoter, was used to normalize the transfection efficiency.
Results
Costimulation by IL-6, GM-CSF or IFN-␥ restores TPAinduced differentiation of v-Myc-expressing U-937 cells
Our previous finding that IFN-␥ abrogated the block of differentiation in v-Myc-expressing U-937 cells raised the question whether other cytokines might have a similar effect on the differentiation of these cells. During monocyte differentiation expression of the adhesion molecule CD11c (␣X-integrin/p150.95) is upregulated both in normal monocytes and monocytic cell lines. 31, 32 Expression of CD11c is also a common feature of U-937 differentiation induced by several different agents which otherwise lead to distinct antigenic phenotypes. 33 Figure 1a shows that differentiation of the parental clone, U-937-GTB, and a U-937-neo control clone was induced by TPA (resulting in 80-95% CD11c-positive cells) measured after 96 h of induction. In contrast, the two v-Mycexpressing U-937 clones, U-937-myc-2 and U-937-myc-6, were inhibited in their differentiation, as evidenced by the much weaker increase in the percentage of CD11c-expressing cells. It should be pointed out that the initial response to TPA is normal in U-937-myc cells, and is followed by regained proliferation and an abortion of the differentiation program after 24 h of induction. 12 Most of the increase in CD11c expression can therefore be attributed to the transient effect of TPA (see also Figure 2 ). Notably, also the basal level of Leukemia CD11c expression was reduced in v-Myc-expressing U-937 cells ( Figure 1a and Figure 3 ).
Next we examined the effect of 16 different cytokines, IL-1, IL-3, IL-4, IL-6, IL-7, IL-10, IL-11, LIF, OSM, M-CSF, G-CSF, GM-CSF, TGF␤1, TNF-␣, IFN-␣ and IFN-␥, with respect to their capacity to induce differentiation in U-937-myc cells. In previous experiments we have shown that terminal differentiation required the combination of TPA and IFN-␥, neither one alone was sufficient. 24 Therefore, the above cytokines were also combined with TPA. The results are summarized in Figure 1b . A significant increase (P Ͻ 0.05) in the expression of CD11c was observed after stimulation by IL-6, GM-CSF, IL-4, and IFN-␥ alone for 96 h. In combination with TPA, the costimulation by IL-6 or GM-CSF, and to a lesser extent IL-4, increased the expression of CD11c even further. The combination of TPA and IFN-␥ induced CD11c expression effectively, as previously reported. 24 However, the stimulation by IL-1, IL-3, IL-7, IL-10, IL-11, LIF, OSM, M-CSF, G-CSF, TGF␤1, TNF-␣ or IFN-␣, with or without TPA, induced only marginal differentiation of the U-937-myc cells, as judged by the CD11c expression. Since IFN-␥ in combination with TPA is such a potent inducer of differentiation in U-937-myc cells it is notable that concentrations of IFN-␣ up to 1000 U per ml showed only a weak differentiating effect (Figure 1b and data not shown). Moreover, no significant enhancement was observed after induction when IL-4, IL-6, GM-CSF or IFN-␥ was combined with IL-1, M-CSF or TGF␤1 (Figure 1c ). In contrast, the increase in CD11c expression, induced by IL-4, IL-6 and GM-CSF, was suppressed by the addition of TGF␤1. To further substantiate the acquisition of a differentiated phenotype the expression of CD11b (␣M-integrin/CR3) was measured. After stimulation by IL-6, GM-CSF, and IFN-␥ an increased expression of CD11b was observed, indicative of monocytic differentiation ( Figure  1d ). However, similar to CD11c, no increase in CD11b expression was seen after stimulation by TGF␤1. Finally, pairwise combinations of the cytokines which yielded a positive differentiation inducing effect, ie IL-4, IL-6, GM-CSF and IFN-␥, showed only a marginally better result (data not shown), suggesting that the contribution by the TPA-induced signal is important for the differentiation process.
Kinetics and concentration dependence of cytokineinduced differentiation
To study the kinetics and concentration dependence of cytokine-induced differentiation, U-937-myc-6 cells were induced by selected cytokines ± TPA. First, the expression of CD11c was analyzed during a time course of 120 h. The increase in CD11c expression induced by IL-6, GM-CSF or IFN-␥ alone, and by the combination IL-6 + GM-CSF, occurred relatively late, around 96 h (Figure 2) . However, the kinetics of induction was much more rapid when TPA was included; the combinations TPA + IL-6, TPA + IL-6 + GM-CSF and TPA + IFN-␥, resulted in a significant increase in CD11c expression within 48 h. Also, the combination of TPA + GM-CSF resulted in a moderate increase in CD11c expression, peaking at 96 h. In contrast, TGF␤1 did not induce expression of CD11c during the time studied. As a result of the initially normal response to TPA in U-937-myc cells before reversion, 12 a slight transient increase in CD11c expression after TPA induction was observed.
To study the dose response of cytokine-induced differentiation, the expression of CD11c was analyzed in the U-937- GTB, U-937-neo-6, U-937-myc-2 and U-937-myc-6 clones after 96 h of stimulation by increasing concentrations of GM-CSF or IL-6 ± TPA. GM-CSF in combination with TPA induced an increase in CD11c expression to around 40% positive cells at 50 U per ml (Figure 3a) . A strong differentiating effect was, again, observed for the combination of TPA + IL-6, with a significant stimulation of CD11c expression at 50 U per ml of IL-6 (Figure 3b ).
IL-6, GM-CSF, TGF␤1 and IFN-␥ induce growth inhibition and accumulation of cells in the G 0 /G 1 phase of the cell cycle
Terminal differentiation of U-937 cells is accompanied by growth arrest in the G 1 /G 0 phase of the cell cycle. 24, 33 To investigate the effects of IL-6, GM-CSF, TGF␤1 and IFN-␥ ± TPA on the growth of U-937-myc cells, cell numbers were counted at 96 h after induction (Figure 4a) . As a consequence of TPA-induced differentiation, the number of U-937-neo-6 cells was significantly lower than for untreated cells. The U-937-myc-6 cell numbers were also somewhat reduced after TPA induction compared to untreated values. This is a result of the transient growth inhibition seen within the first 24 h of TPA treatment. 12 As reported previously, 24 IFN-␥ treatment led to a strong inhibition of cell growth that was further enhanced by TPA. Treatment with IL-6, GM-CSF or TGF␤1 resulted in less dramatic growth inhibitory effects than IFN-␥; IL-6 and GM-CSF stimulation decreased the cell numbers by 40-50% compared to untreated cells, but combined treatment with TPA led to a further reduction. Notably, TGF␤1, which did not stimulate differentiation (Figures 1 and 2) , induced growth inhibition to a similar extent as IL-6 and GM-CSF (Figure 4a ).
To estimate ongoing DNA synthesis in the cultures, the incorporation of 3 H-thymidine ( 3 H-TdR) was measured at 96 h after induction. As seen in Figure 4b , U-937-neo-6 cells displayed a markedly reduced 3 H-TdR incorporation after TPA induction, whereas TPA-treated U-937-myc-6 cells had regained their proliferative capacity at this time point, and therefore incorporated similar levels of (Figure 4b ). The addition of TPA did in most cases not lead to further reduction of DNA synthesis at this time point. To investigate to what extent apoptosis contributed to the observed reduction in cell numbers and DNA synthesis, the fraction of U-937-myc-6 cells double-positive for annexin V/7-amino-actinomycin (7-AAD) after induction by IL-6, GM-CSF, TGF␤1 and IFN-␥ was measured. A significant increase in apoptosis was observed only for IFN-␥ and TPA + IFN-␥, with 30-40% apoptotic cells after 72 h (Figure 4c ). We thus concluded that while apoptosis Leukemia contributed substantially to the IFN-␥-induced growth inhibition, the major part of the IL-6, GM-CSF and TGF␤ responses were likely to be direct effects on cell proliferation.
To further investigate the proliferative responses, the expression of histone H4 mRNA, which is regulated in a cell cycle-dependent fashion, 34 was measured in cytokine-and/or TPA-treated U-937-myc-6 and U-937-neo-6 control cells by Northern blot analysis. The results showed that H4 mRNA expression was reduced upon TPA induction in U-937-neo-6 cells but not in U-937-myc-6 cells ( Figure 5 ). However, the H4 mRNA expression was significantly reduced after cytokine induction in both U-937-neo-6 and U-937-myc-6 cells. The reduction in H4 mRNA levels was at least 50% after induction by IL-6 or IFN-␥, slightly less for GM-CSF, and most pronounced after treatment by TGF␤1, as compared to untreated U-937-myc-6 cells by scanning of the film. This is consistent with the observed reduction in proliferation. Similar to the 3 HTdR results, addition of TPA did not result in a further reduction in H4 expression. The low GAPDH levels after TGF␤1 + TPA treatment was not due to RNA loading differences as judged by ethidium bromide staining of the gel.
To determine if the reduced proliferation was associated with arrest in the G 1 /G 0 phase of the cell cycle, FACS analysis of the cell cycle distribution was performed. The results are summarized in Table 1 . The control clone U-937-neo-6 responded to TPA-induced differentiation by an increase of the fraction of cells in G 1 /G 0 whereas U-937-myc-6 cells failed to arrest in G 1 /G 0 , consistent with their inhibited terminal differentiation. However, costimulation of TPA with IFN-␥ resulted in an accumulation of v-Myc-expressing cells in G 1 /G 0 , as previously reported. 24 Interestingly, induction by TGF␤1 alone resulted in a prominent G 1 /G 0 arrest, which was somewhat further enhanced by TPA costimulation in both U- 937-myc-6 and U-937-neo-6 cells (Table 1 ). An increase of the proportion of cells in the G 1 /G 0 phase of the cell cycle was also noted after the induction by IFN-␥, GM-CSF and IL-6 alone. Combination of these cytokines with TPA resulted in further G 1 /G 0 accumulation of the same magnitude as that observed in TPA-treated U-937-neo-6 cells.
Reduced Myc activity during cytokine-induced differentiation and/or growth arrest
To determine whether the expression of the v-or c-Myc proteins was affected by cytokine ± TPA treatment, lysates from U-937-myc-6 cells were immunoprecipitated by pan-Myc antibodies and subjected to Western blot analysis. We have shown previously that IFN-␥ and in particular TPA + IFN-␥ reduce v-and c-Myc activity in U-937-myc-6 cells through a post-translational mechanism. 25 To address whether IL-6, GM-CSF and TGF␤1 affected v-and c-Myc activity in a similar way, we first assessed the transactivating capacity of Myc in these cells. A Myc-regulated promoter/luciferase reporter construct (m4mintk-Luc) was therefore transfected into U-937-myc-6 cells, whereafter the transfected cells were divided into aliquots and stimulated with cytokines ± TPA. Figure 6b shows that IFN-␥ and TPA + IFN-␥ reduced Myc Ebox-dependent transcription to 38 and 26% of controls, respectively, in agreement with our previous report. 25 IL-6 and GM-CSF stimulation also reduced promoter activity, although to a lesser extent than IFN-␥ (56 and 71% of control, respectively). This activity was somewhat further reduced by the addition of TPA. TGF␤, on the other hand, induced a very strong reduction in promoter activity (8% of control, Figure  6b ). Since the major part of the m4mintk-Luc promoter activity has been shown to be Myc-dependent in U-937 cells, 25 we concluded that the activity of v/c-Myc was also regulated to various degrees by cytokine-induced signals other than IFN-␥. The Myc activities measured seemed to correlate fairly well with the expression of histone H4 ( Figure 5 ) and the cell cycle distribution of the cells (Table 1) , thus suggesting that the Myc proteins are at least one important target for the cytokineinduced anti-proliferative signals. To shed some light on the mechanism(s) of the cytokine-induced anti-Myc activities, we measured v-and c-Myc association with its obligatory partner Max, which is required for Myc activity. Max was immunoprecipitated from lysates under low stringency conditions to preserved Myc:Max complexes, and the amount of v-and c-Myc Cytokine-induced inhibition of proliferation, DNA synthesis, and apoptosis. U-937-neo-6 and -myc-6 cells were seeded in fresh medium at a concentration of 150 000 cells/ml and induced by the indicated cytokines alone (white bars), or in combination with TPA (black bars) for 96 h. 
Figure 5
Expression of histone H4 mRNA. U-937-neo-6 and -myc-6 cells were induced by the indicated cytokines and combinations with TPA for 72 h. Total RNA (10 g per lane) was separated on a formaldehyde containing agarose gel and transferred to a nitrocellulose filter. The filter was hybridized to a 0.7 kb EcoRI-HindIII fragment of a human histone H4 cDNA and as reference a 0.9 kb HindIII-XbaI fragment of human GAPDH.
in those complexes were measured by Western blot analysis using pan-Myc antibodies. As reported previously, 25 the amounts of co-immunoprecipitated v-and c-Myc were reduced in IFN-␥ and in particular in TPA + IFN-␥-treated cells, indicative of a reduction in Myc:Max heterodimerization (Figure 6a, middle panel) . Reduced v-and c-Myc:Max heterodimerizations were also apparent in TGF␤ and TGF␤ + TPALeukemia Table 1 Cell cycle distribution of U-937 clones TPA neo-6 myc-6 U-937-myc-6 cells were transfected with 20 g of m4mintk-Luc together with 1 g of CMV-LacZ. m4mintk-Luc contains four copies of the Myc:Max E-box binding site CACGTG in front of a minimal tk promoter linked to a luciferase reporter gene. 25 After transfection, the cells from separate transfections were pooled and divided into aliquots, which were then treated with the inducers, as indicated in the figure, for 18 h. For TGF␤1, the cells were induced for 2 days before transfection. Cell extracts were prepared and the m4mintk-Luc promoter activity was measured by luciferase assay. The presented data are normalized to ␤-gal activity and shown as percentage of control cells. n.d., not determined. 
Discussion
Our previous work has demonstrated that constitutive v-Myc expression in U-937 cells blocks terminal differentiation, as defined by growth arrest in the G 0 /G 1 phase of the cell cycle and expression of antigens associated with monocytic differentiation, and that this block can be abrogated by IFN-␥ in combination with TPA, retinoic acid or vitamin D3. 12, 24, 25 Based on these results, we have examined the effects of 16 cytokines with respect to differentiation and growth arrest in this cell model. The results show that IL-6 and GM-CSF, and to a lesser extent IL-4, as single agents could induce a partial differentiation of v-Myc-expressing U-937 cells. For terminal differentiation, however, costimulation with TPA was required. In contrast, TGF␤1 induced a specific G 0 /G 1 arrest without the induction of CD11c or CD11b expression, irrespective of the presence of TPA. Importantly, the p57 v-Myc protein was continuously expressed during cytokine-induced differentiation and G 0 /G 1 arrest in the cell cycle.
The murine myeloid leukemia cell line, M1, provides an analogous system in which constitutive c-Myc expression has been shown to inhibit IL-6-or LIF-induced terminal differentiation at an intermediate stage. 13, 14 In these cells induction by IL-6 or LIF resulted in the expression of certain differentiationrelated markers but the expression of late differentiation markers and growth arrest in the G 0 /G 1 phase of the cell cycle was prevented. These results are similar to our observation, in that induction by IL-6, GM-CSF, IL-4 or IFN-␥ alone led to a partial differentiation and a partial accumulation of the cells in G 0 /G 1 . The receptors for IL-4, IL-6, GM-CSF and IFN-␥ all share activation of the signal transducer and activator of transcription (Stat) transcription factor family via associated Janus kinases (JAKs) as an important part of their signal transduction (reviewed in Ref. 35) . By the use of dominant-negative Stat3 it was shown that IL-6-induced activation of Stat3 is required for differentiation of M1 cells. 36 Also, transcriptionally active Stat1 has been shown to be necessary for IFN-␥-induced antiproliferative effects, 37 and Stat1, Stat3 and Stat5 have been suggested to regulate the cyclin-dependent kinase inhibitor p21 WAF1 promoter through common GAS-binding sites as part of the growth inhibition mediated by IFN-␥, IL-6 and TPO, respectively. [38] [39] [40] Thus, signals induced by IL-6, GM-CSF, IL-4 and IFN-␥, likely mediated by the JAK-Stat pathway, might converge at a point critical for the restoration of differentiation and cell cycle arrest in U-937-myc-6 cells. However, we observed some differences in their action, eg IFN-␥ was the only cytokine that induced apoptosis, which contributed to the pronounced reduction in cell numbers. Interestingly, although IFN-␥ and IFN-␣ have overlapping signal transduction pathways, and despite the fact that IFN-␣ has previously Reduced Myc activity during cytokine-induced differentiation and growth arrest F Ö berg et al 225 been shown to increase TPA-induced differentiation of resistant HL-60 cells, 41 we did not find that IFN-␣ could restore differentiation of U-937-myc cells. Although IL-6, GM-CSF and IFN-␥ could induce partial differentiation, growth inhibition and partial accumulation in the G 1 phase of the cell cycle as single agents, costimulation with TPA led to a higher developed differentiated phenotype and fully developed G 1 arrest. This latter phenotype appear to represent a quantitatively and qualitatively distinct state often referred to as 'terminal differentiation', an irreversible state characterized by deep and permanent G 1 arrest. This state is normally induced by TPA alone in U-937 cells, but the pathway leading to this state is inhibited by Myc. Our present model suggests that cytokine-induced signals (enhanced by TPA) directly or indirectly inhibit Myc activity thus opening the way for TPAinduced terminal differentiation (see further discussion below).
In contrast to IL-6, GM-CSF, IL-4 and IFN-␥, induction of U-937-myc cells by TGF␤1, which utilizes Ser/Thr kinase receptors and the Smad proteins for signal transduction, 42 resulted in a pronounced G 0 /G 1 arrest without signs of terminal differentiation. Furthermore, the induction of CD11c expression by IL-4, IL-6, and GM-CSF was inhibited by the addition of TGF␤1. This result differs from a previous report showing synergism between TGF␤1 and IFN-␥ or TNF-␣ for the induction of differentiation of U-937 cells, 43 although in agreement with this report, we observed synergism between these cytokines with respect to growth arrest (data not shown). TGF␤1 inhibits the proliferation of several cell types in vitro and it has been suggested that this inhibitory effect is mediated, in part, by the down-regulation of c-myc at the level of transcription. 44, 45 However, since we show that v-Myc expression is not down-regulated by TGF␤1 (Figure 6 ), it is likely that the TGF␤1-induced signals counteract the activity rather than the expression of Myc in these cells (see below). Reports from other cell systems have shown that constitutive c-Myc expression abrogates TGF␤-induced cell cycle arrest in fibroblasts, 46 and more recently in epithelial cell lines. 47 This, however, apparently does not occur in the U-937-myc system. The reason for this discrepancy is unclear but may reflect differences in Myc expression levels, such that the expression level of Myc in U-937-myc cells is sufficient to block TPAinduced differentiation and cell cycle arrest, but may be below a certain threshold level required to block TGF␤ action. Alternatively, the discrepancy may be attributed to cell typespecific differences in TGF␤ signaling.
There are at least three, principally different, mechanisms that could account for the cytokine-induced restoration of differentiation in U-937-Myc cells. Leukemia and a number of other types of genes of relevance for cellular homeostasis. 2 Our results show that IL-6, GM-CSF, TGF␤ and IFN-␥ ± TPA, to various degrees, all reduced Myc E-box-dependent transcription of an artificial Myc-target promoter/reporter construct. Since we have previously shown that the major part of this promoter activity is Myc-dependent in U-937 cells, 25 we can therefore conclude that the cytokines indeed reduced Myc activity. The measured activities of Myc correlated well with the expression of the cell cycle marker gene histone H4 and the cell cycle distribution of the cells, thus suggesting that Myc proteins are at least one important target for the cytokineinduced anti-proliferative signals. Either of the first two hypotheses described above therefore seem relevant mechanisms for such anti-Myc activities.
Co-immunoprecipitations of v-and c-Myc together with its essential binding partner Max showed that the reduced Myc activity towards its target promoter in response to cytokine ± TPA treatments in most, but not all cases (see below), correlated well with reduced v-and c-Myc:Max heterodimerization. In the case of IFN-␥ ± TPA, our recent observations suggest that the destabilization of Myc:Max heterodimers is linked to dephosphorylation of v-and c-Myc, 25 which speaks in favor of a direct effect on Myc activity. Cytokine-induced expression of Mad-family members, as alternative partners of Max binding the same type of E-boxes as Myc:Max, is an alternative way of reducing Myc:Max heterodimerization and of suppressing Myc-dependent transcription. 48, 49 In support of this idea, one report has suggested that differentiation in MEL cells blocked by c-Myc can be restored by overexpression of Mad. 50 Indeed, our recent data suggest that TGF␤1 in contrast to IFN-␥ induces high and sustained expression of Mad1 in U-937-myc-6 cells (S Wu, A Hultquist, F Ö berg and L-G Larsson, manuscript in preparation), which may explain the reduced Myc:Max heterodimerization and Myc-dependent transcription in response to TGF␤ presented in this report.
IL-6 and GM-CSF ± TPA also reduced Myc-dependent transcription, although to a lesser extent than IFN-␥ and TGF␤, correlating with the level of reduction in histone H4 mRNA expression and the cell cycle distribution. A corresponding reduction in v/c-Myc:Max heterodimerization was observed in response to IL-6 and GM-CSF, suggesting that modifications of Myc, as suggested in the case of IFN-␥, induction of Madproteins, as suggested for TGF␤, or other events destabilizing Myc:Max heterodimers may have occurred. IL-6 and GM-CSF when combined with TPA did, however, not result in reductions of v-Myc:Max heterodimerization despite the reductions in Myc-dependent transcription. The reason for this is unclear at present, but may possibly involve mechanisms affecting the activity of the transactivation domain of Myc.
Elucidation of the precise mechanism by which IL-6 and GM-CSF alone or in combination with TPA inhibit Myc activity awaits further investigation.
In conclusion, our results argue that it is indeed possible to find cytokines, or combinations of cytokines and other signals, that can be used to inhibit Myc activity and thereby contribute to the re-establishment of terminal differentiation and growth arrest in tumors characterized by deregulated myc expression. However, the capacity of individual cytokines to affect growth and differentiation of a particular tumor is likely to be dependent on cell type, maturation stage, and additional genetic defects. Nevertheless, this finding can be used as a basis for a further search for combinations of signals that may be of therapeutic value in the treatment of tumors having amplified or translocated myc genes.
